NCT07277075

Probiotic Intervention and Its Influence on Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Acne Vulgaris Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: Benha University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aimed to assess the serum level of Leucine-rich alpha-2 glycoprotein 1 (LRG1) in Acne vulgaris (AV) individuals and evaluate the effect of probiotic therapy on these serum levels.

Detailed description

Acne vulgaris (AV) is a common inflammatory disorder of the pilosebaceous units, characterized by the presence of inflammatory, non-inflammatory, or a combination of both types of lesions. Recent attention has turned toward biomarkers that reflect the inflammatory activity in acne and might act as indicators of disease severity, treatment response, or prognostic risk. One such candidate is Leucine-rich alpha-2 glycoprotein 1 (LRG1). Probiotics are live microorganisms that, when administered in sufficient quantities, can modulate the composition of the gut microbiota, helping reduce microbial dysbiosis, regulate the immune response, and decrease inflammatory mediators, thereby reducing systemic inflammatory burden, which is called the gut-skin-axis relationship.

Conditions

• Probiotic
• Influence
• Serum Leucine-Rich Alpha-2 Glycoprotein 1
• Acne Vulgaris

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) level	Serum Leucine-rich alpha-2 glycoprotein 1 (LRG1) levels were assessed in acne vulgaris participants and healthy controls.

Timeline

• Start date: 2024-10-01
• Primary completion: 2025-09-30
• Completion: 2025-09-30
• First posted: 2025-12-11
• Last updated: 2025-12-11

Locations

1 site across 1 country: Egypt